| AR | Androgen receptor |
| CAF | Cancer-associated fibroblast |
| ECM | Extracellular matrix |
| EMT | Epithelial–mesenchymal transition |
| ER | Estrogen receptor |
| HIF | Hypoxia-inducible factor |
| IBC, NST | Invasive breast carcinoma of no special type |
| iCAF | Inflammatory cancer-associated fibroblast |
| IM | Immunomodulatory subtype |
| LAR | Luminal androgen receptor subtype |
| M | Mesenchymal subtype |
| MMP | Matrix metalloproteinase |
| MSL | Mesenchymal stem-like subtype |
| myCAF | Myofibroblast-like cancer-associated fibroblast |
| NAC | Neoadjuvant chemotherapy |
| pCR | Pathological complete response |
| PR | Progesterone receptor |
| TGF-β | Transforming growth factor beta |
| TME | Tumor microenvironment |
| TNBC | Triple-negative breast cancer |
| VDR | Vitamin D receptor |